New asthma pill shows potential benefits in severe cases

A new asthma pill has been described as a potential "game-changer" in the treatment of severe forms of the condition.

Led by the University of Leicester and funded by Novartis, a study was launched to assess the performance of Fevipiprant, which represents the first new asthma pill for nearly 20 years.

The drug was shown to significantly decrease the symptoms of asthma, improve lung function, reduce inflammation and repair the lining of airways when taken by those with severe asthma.

Based on these findings, it is believed the new pill could help to head off preventable asthma attacks, reduce hospital admissions and improve day-to-day symptom management.

Professor Christopher Brightling from the university's department of infection, immunity and inflammation said: "Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests."

Fevipiprant is currently being evaluated in late-stage clinical trials to assess its efficacy in patients with severe asthma.

With over 20 years of experience within the science market, we at Zenopa have the knowledge skill and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.